Drug General Information |
Drug ID |
D05XEA
|
Former ID |
DNCL003132
|
Drug Name |
RP5063
|
Indication |
Schizoaffective disorder; Schizophrenia [ICD9: 295, 295.70; ICD10:F20, F25]
|
Phase 2 |
[1]
|
Company |
Reviva Pharmaceuticals
|
Target and Pathway |
Target(s) |
5-hydroxytryptamine 1A receptor |
Target Info |
Antagonist |
[2],
[3]
|
D(2) dopamine receptor |
Target Info |
Antagonist |
[2],
[3]
|
KEGG Pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Serotonergic synapsehsa04015:Rap1 signaling pathway
|
Gap junction
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Alcoholism
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Dopamine receptor mediated signaling pathway
|
Nicotine pharmacodynamics pathway
|
Reactome
|
Serotonin receptors
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Serotonin HTR1 Group and FOS Pathway
|
SIDS Susceptibility Pathways
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCR ligand binding
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCR downstream signaling
|
Nicotine Activity on Dopaminergic Neurons
|
References |
REF 1 | ClinicalTrials.gov (NCT01490086) RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder. U.S. National Institutes of Health. |
---|
REF 2 | Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271 |
---|
REF 3 | EFFICACY AND SAFETY OF NOVEL DOPAMINE SEROTONIN STABILIZER RP 5063 IN ACUTE SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER. Schizophrenia Research Volume 153, Supplement 1, April 2014, Pages S22. |